![]() | This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
|
It's out of date. Needs updating and possibly restructuring by cancer type ? - Rod57 ( talk) 15:14, 18 November 2011 (UTC)
There is a banner claiming that this is written like an advertisement. The drug Reolysin is purely at an experimental phase right now and IT IS NOT APPROVED FOR SALE ANYWHERE IN THE WORLD, so it is certainly not being advertised. The National Cancer Institute in the USA and the National Cancer Institute in Canada are both conducting large clinical trials of this agent, and putting up roughly $40M or so of funding for these trials. So I think it is reasonable to assume that the science for this experimental agent looks encouraging (as of Oct 2012) and that the article simply reflects this fact. 99.235.250.152 ( talk) 22:13, 31 October 2012 (UTC)
The name reolysin is no longer the proposed trade name for this drug, due to name collision with marketed pharmaceuticals. I suggest that the article be moved to its generic name pelareorep.
The result of the move request was: Moved. ( non-admin closure) DBig Xrayᗙ 15:16, 6 September 2019 (UTC)
Reolysin →
Pelareorep – The name "Reolysin" has been deprecated due to name collision. The innovator, Oncolytics Biotech, has stopped using the term "Reolysin" and instead is using the proposed USAN (i.e., generic) name. The innovator explains this on their web site. This is by no means controversial and under the guidelines would have been permitted and encouraged without this formal move process, but here we are.
Sbelknap (
talk)
14:42, 6 September 2019 (UTC)
An editor has identified a potential problem with the redirect
REOLYSIN® and has thus listed it
for discussion. This discussion will occur at
Wikipedia:Redirects for discussion/Log/2022 April 15#REOLYSIN® until a consensus is reached, and readers of this page are welcome to contribute to the discussion.
BD2412
T
05:07, 15 April 2022 (UTC)
![]() | This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
|
It's out of date. Needs updating and possibly restructuring by cancer type ? - Rod57 ( talk) 15:14, 18 November 2011 (UTC)
There is a banner claiming that this is written like an advertisement. The drug Reolysin is purely at an experimental phase right now and IT IS NOT APPROVED FOR SALE ANYWHERE IN THE WORLD, so it is certainly not being advertised. The National Cancer Institute in the USA and the National Cancer Institute in Canada are both conducting large clinical trials of this agent, and putting up roughly $40M or so of funding for these trials. So I think it is reasonable to assume that the science for this experimental agent looks encouraging (as of Oct 2012) and that the article simply reflects this fact. 99.235.250.152 ( talk) 22:13, 31 October 2012 (UTC)
The name reolysin is no longer the proposed trade name for this drug, due to name collision with marketed pharmaceuticals. I suggest that the article be moved to its generic name pelareorep.
The result of the move request was: Moved. ( non-admin closure) DBig Xrayᗙ 15:16, 6 September 2019 (UTC)
Reolysin →
Pelareorep – The name "Reolysin" has been deprecated due to name collision. The innovator, Oncolytics Biotech, has stopped using the term "Reolysin" and instead is using the proposed USAN (i.e., generic) name. The innovator explains this on their web site. This is by no means controversial and under the guidelines would have been permitted and encouraged without this formal move process, but here we are.
Sbelknap (
talk)
14:42, 6 September 2019 (UTC)
An editor has identified a potential problem with the redirect
REOLYSIN® and has thus listed it
for discussion. This discussion will occur at
Wikipedia:Redirects for discussion/Log/2022 April 15#REOLYSIN® until a consensus is reached, and readers of this page are welcome to contribute to the discussion.
BD2412
T
05:07, 15 April 2022 (UTC)